SHORT TERM EFFECT OF SELEXIPAG IN COMPARISON TO PROSTACYCLIN ANALOGUES IN PULMONARY ARTERIAL HYPERTENSION PATIENTS STARTED ON DOUBLE-COMBINATION THERAPY WITH ERA AND PDE-5 INHIBITORS

GRIPHON trial demonstrated that Selexipag reduces morbi-mortality events in patients with pulmonary arterial hypertension (PAH) but its efficacy in comparison to prostacyclin analogues in patients already on oral double-combination therapy with endothelin receptor antagonist (ERA) and